aTyr Pharma (ATYR)
(Real Time Quote from BATS)
$0.71 USD
+0.02 (2.84%)
Updated Oct 2, 2025 03:02 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ATYR 0.71 +0.02(2.84%)
Will ATYR be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ATYR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATYR
Is aTyr Pharma (ATYR) Stock Outpacing Its Medical Peers This Year?
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates
ATYR: What are Zacks experts saying now?
Zacks Private Portfolio Services
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Tops Revenue Estimates
Other News for ATYR
Leerink Partners Remains a Hold on aTyr Pharma (ATYR)
Is ATYR poised for a decline? New 52 Week Closing Low shows up after dropping 4.3%
New 52 Week Closing Low appears for ATYR after 9.28% move
aTyr Pharma, Inc. (ATYR) Presents at The ERS Congress 2025 - Slideshow
Cautious Hold Rating for aTyr Pharma Amid Mixed Clinical Trial Results and Regulatory Uncertainty